Caricamento...
Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
BACKGROUND: In 2014, lurasidone, an atypical antipsychotic, was approved for the treatment of schizophrenia in adults. It is an alternative treatment option to aripiprazole, and when compared with aripiprazole, lurasidone was associated with improved symptom reduction and reduced risk of weight gain...
Salvato in:
| Pubblicato in: | Pharmacoeconomics |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Springer International Publishing
2016
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4901121/ https://ncbi.nlm.nih.gov/pubmed/27067724 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-016-0405-0 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|